West Cancer Center has received IRB approval to join IceCure’s 400-patient ChoICE post-market study of ProSense in women aged 70 and older with small, biologically low-risk breast cancers.
IceCure Medical launches the ChoICE post-market study at West Cancer Center, testing ProSense adoption and five-year outcomes in breast cancer.
IceCure Medical’s FDA-authorised breast cancer cryoablation platform is gaining United States installations, but narrow eligibility, postmarket evidence requirements and heavy dilution complicate the small-cap investment case.